Carl Zeiss Meditec officials are boasting a strong start to their present fiscal year, announcing that revenue increased to €323.6 million ($382.4 million) during the company’s first quarter.
Revenue for the quarter ended Dec. 31 was up 9.8% year over year. Earnings before interest and taxes also increased, up 23.7% to €48.1 million ($56.4 million).
The company’s ophthalmic devices business saw its revenue increase by 10.7%, to €239.5 million ($283 million), driven by laser vision correction systems and devices and consumables in cataract surgery. The microsurgery business’s revenue was up 7.4%, to €84.2 million ($99.5 million), with strong sales of neurosurgical visualization systems for the treatment of tumors and vascular disease.
“We have made a successful start to the new financial year and were able to further expand our market share in both strategic business units,” said Ludwin Monz, president and CEO of Carl Zeiss Meditec AG.
